Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma

Abstract excerpt

We investigated the effectiveness of navtemadlin (KRT-232) in treating recurrent glioblastoma. A surgical window-of-opportunity trial ( NCT03107780 ) was conducted on 21 patients to determine achievable drug concentrations within tumor tissue and examine mechanisms of response and resistance. Both 120 mg and 240 mg daily dosing achieved a pharmacodynamic impact. Sequencing of three recurrent tumors revealed an abs...

Topics

Open a Topic to create a Post that cites this publication.

• Clinical Decision-Making
• Combined Modality Therapy
• Disease Management
• Disease Progression
• Exome Sequencing
• Glioblastoma
• Immunohistochemistry
• Recurrence

Identifiers and source

Literature Corpus work

f0f087c5-0d06-53e1-a4fe-1f1414285894

DOI

10.1101/2024.08.12.24311893